Merck's Q2 Preview: Building a Post-Keytruda Future Amidst Headwinds

RAHWAY, NJ – July 01, 2026

Merck has officially circled August 4 on the calendar for its second-quarter 2026 earnings call, a routine announcement that belies the high-stakes drama unfolding behind the scenes. While company executives will provide the requisite overview of sales and profits to investors and analysts, the real story lies beyond the immediate balance sheet. The central question is whether Merck's aggressive strategy of acquisitions, pipeline acceleration, and technological partnerships is building a durable foundation strong enough to withstand the seismic shock of its blockbuster drug, Keytruda, losing patent protection in 2028. The upcoming call is not just a financial report card; it's a critical progress update on one of the pharmaceutical industry's most ambitious and expensive corporate reinventions.

A Look Back to Look Forward: Setting the Stage from Q1

To understand the stakes for Q2, one must first look at the company's first-quarter performance, which presented a complex picture of underlying strength masked by strategic spending. Merck posted total revenues of $16.3 billion, a 5% year-over-year increase that comfortably beat analyst expectations. This growth was powered by the continued dominance of its oncology franchise, with the KEYTRUDA family of products climbing 8% to $8.0 billion on strong demand in metastatic and earlier-stage cancers. The animal health division also delivered robust results, with sales up 13% to $1.8 billion. However, this top-line success was paired with a significant GAAP and non-GAAP loss of $1.28 per share. This was entirely attributable to a massive $3.62 per share one-time charge related to the acquisition of Cidara Therapeutics, a clear signal of management's willingness to absorb short-term financial pain for long-term pipeline assets.

Not all product lines showed momentum. Sales of the HPV vaccine Gardasil fell by a startling 22%, a decline driven by flagging demand in China and Japan. This weakness in a franchise once seen as a reliable growth engine raises questions that will undoubtedly be a focus of the Q2 call. Despite the mixed signals, management raised its full-year non-GAAP EPS guidance to a range of $5.04 to $5.16. Yet, this updated forecast was perceived by some on Wall Street as conservative, suggesting that significant uncertainties, or perhaps more acquisition-related charges, are anticipated for the second half of the year.

The $25 Billion Question: Navigating the Keytruda Cliff

The entire strategic narrative at Merck revolves around a single, looming date: 2028. That is when the core patents for Keytruda, a drug that generates nearly half of the company's pharmaceutical revenues, are set to expire. The introduction of biosimilar competition could erase an estimated $25 billion in annual revenue, creating a potential financial abyss that the company is frantically working to fill. The Q2 earnings call will be scrutinized for evidence that this monumental effort is gaining traction.

Merck’s strategy is a two-pronged assault of internal innovation and external acquisition. Internally, the company is banking on a portfolio transformation driven by what it projects as over 20 new product launches, many with blockbuster potential. Recent progress has been encouraging. On June 25, the FDA approved a combination of KEYTRUDA with Trodelvy for a specific subset of advanced triple-negative breast cancer patients, a move that both expands the drug's reach and showcases a strategy of maximizing its value before patent loss. This was followed by an expanded indication for its pediatric pneumococcal vaccine, Capvaxive. With significant Phase 3 data readouts expected over the next 18 months, any updates on trial progress or regulatory timelines shared on the August call will be parsed as vital indicators of future growth.

Forging the Future with Data and Deals

Complementing its internal R&D is an aggressive M&A campaign designed to buy future revenue streams. The charges that dragged down Q1 earnings are a direct result of this strategy. Beyond the Cidara deal, Merck's proposed acquisition of Terns Pharmaceuticals is expected to trigger another massive one-time R&D charge of $5.8 billion, or $2.35 per share. These are not accounting footnotes; they are multi-billion-dollar down payments on a post-Keytruda portfolio. This approach mirrors a broader industry trend where large pharmaceutical players are acquiring smaller biotech firms to replenish their pipelines, as exemplified by German-based Merck KGaA's recent $11.3 billion deal to acquire Bio-techne.

Underpinning this entire effort is a significant investment in technology. A recently announced multiyear partnership with Google Cloud aims to embed advanced AI capabilities across Merck's operations, accelerating drug discovery and development. This builds on existing collaborations with data science firms like Tempus AI and the Mayo Clinic. In a race against a patent clock, leveraging AI to find efficiencies and speed up timelines is not a luxury but a strategic necessity. Investors will be listening for any early metrics or milestones that suggest these technology partnerships are beginning to bear fruit.

Headwinds and High Stakes in a Shifting Market

While Merck executes its grand strategy, it must also navigate a series of immediate market challenges. The sharp decline in Gardasil sales is a primary concern, with analyst reports flagging demand softness in China as a potential structural risk to what has been the company's second-largest franchise. A convincing turnaround plan is needed. Furthermore, the company faces stiff competition in the lucrative immunology market, where many of its peers boast broader and more established portfolios.

Externally, the operating environment is growing more difficult. As noted in its 2025 10-K filing, Merck and its peers face increasing pricing pressure from state governments implementing drug price transparency laws and other cost-containment measures. This political and regulatory pressure could squeeze margins on the very blockbuster products Merck is counting on to secure its future. The answers provided on August 4 will offer the clearest signal yet of whether Merck's bold, multi-billion-dollar gamble on its future is on track to pay off.